Paclitaxel Induced MDS and AML: A Case Report and Literature Review

Table 1

Case reports of taxane chemotherapy related myelogenous leukemias.

Author	Year	Age	Primary tumor	Docetaxel	Paclitaxel (total dose in mg)	Carboplatin (total dose in mg)	Karyotype	Latency of leukemia (period from initial treatment to onset of AML)	MDS	AML	Prognostic: time from Dx of AML to death
Ishikawa et al. [8]	2014	65	Ovarian cancer		1968	6480	45,XX,der(6)t(6:17)(p23;q21)inv(6)(p23q13),17,; add(19)(p13)4/44,sl-510/46,XX5	3 years 10 months	MDS-RCMD	—	15 m
Vanajakshi et al. [9]	2014	69	Ovarian cancer		1200	2700	53XX; trisomies 8, 12, 16, 18, 19, and +2mar JAK2V617F; 5q31 and 7q31 deletions	33 months	MDS-U	M4	1 m of AML
See et al. [10]	2006	54	Ovarian cancer		1710	6820	Abnormal karyotype with multiple complex abnormalities, including 45XX t(1,5)(q25;q35),del(4); (q21q26),ins(7)(p15;?),del(12)(p12),213,217,217,; add(19)(p13.3),; add(22)(q13),12mar in 11 metaphases and 43–45,XX,t(1;5); (q25;q35),del(4)(q21q26),ins(7)(p15;?); del(12)(p12),213,217,217,add(19)(p13.3),; add(22)(q13),1224mar in 8 metaphases were identified at diagnosis of erythroleukemia	36 months	—	M6	10 m after dx of AML
Yeasmin et al. [11]	2008	73	Ovarian cancer		2085	1910	46,XX,der(5,19)(p10:q10),−6,del(7)(q?),; add(12)(p11.2),−13,−17,+19	24 months	MDS-RAEB	M7	2 m
Kim et al. [12]	2006	64	NSCLC		525	1123	NR	27 months	MDS-CMML		9 m
Gupta et al. [13]	2014	64	Breast cancer		(Dose not specified)		46,XX,t(8;16)(p11.2;p13.3),der(22)t(1;22)(q21;q13)	2 years		M4	1 m
Melichar et al. [14]	2012	54	Ovarian and breast cancer		(Dose not specified)	Cisplatin equivalents 3798 mg	NR	5 years	MDS-RAEB	—	3 m
Melichar et al. [14]	2012	66	Ovarian cancer		31 cycles × 175 mg/m^2	Cisplatin equivalents 4050 mg	NR	43 months		Unclassified	1 m
Christodoulou et al. [15]	2004	21	Mixed germ cell tumor (seminoma)		1000		47,XY,i(5)(p10),del(12)(p11),+i(12)(p10) 18	10 months	MDS (RARS)	—	Survived
Seymour et al. [16]	1999	59	Ovarian cancer		1800	3600	NR	22 months		M4	Survived
Seymour et al. [16]	1999	54-55	Neuroendocrine cancer of ovary		450	750	NR	8 months		M4	10 weeks
Griesinger et al. [17]	2004	74	NSCLC stage IIIB	4 cycles × 100 mg/m^2		4800	NR	40 months	MDS-RA	M2	40 m
Current	2014	63	Endometrial cancer		1511	4312	45,XX,add(3)(p13),del(3)(q23q25),−5,add(5)(q13),; add(7)(q11.2),der(17)t(5,17)(q15;q25)	7.5 months	MDS-RAEB	M4	2 weeks